Boehringer Ingelheim to start Phase 3 BI HCV drug trials
The Phase 3 trials include two studies in treatment-naive and one study in treatment-experienced chronic genotype-1 HCV patients. Boehringer Ingelheim expects to conduct the two Phase 3 studies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.